Holen Sie sich die Stockscreener-App
71.08
0.36%
-0.26
Schlusskurs vom Vortag:
$71.34
Offen:
$70.84
24-Stunden-Volumen:
56,644
Relative Volume:
0.06
Marktkapitalisierung:
$2.05B
Einnahmen:
$915.25M
Nettoeinkommen (Verlust:
$131.14M
KGV:
15.89
EPS:
4.472
Netto-Cashflow:
$96.71M
1W Leistung:
+4.42%
1M Leistung:
-6.13%
6M Leistung:
+36.61%
1J Leistung:
-14.14%
1-Tages-Spanne:
$70.40
$72.50
1-Wochen-Bereich:
$68.33
$71.90
52-Wochen-Spanne:
$38.91
$147.03
Inspire Medical Systems Inc Stock (INSP) Company Profile
Firmenname
Inspire Medical Systems Inc
Sektor
Branche
Telefon
763-957-5037
Adresse
5500 WAYZATA BLVD, GOLDEN VALLEY
Compare INSP vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSP
Inspire Medical Systems Inc
|
71.08 | 2.05B | 915.25M | 131.14M | 96.71M | 4.472 |
ABT
Abbott Laboratories
|
98.70 | 170.80B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.48 | 119.57B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.99 | 113.15B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.20 | 64.05B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.80 | 50.61B | 6.30B | 1.07B | 1.09B | 1.8406 |
Inspire Medical Systems Inc Stock (INSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-07 | Eingeleitet | Barclays | Underweight |
| 2026-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-07-28 | Fortgesetzt | UBS | Sell |
| 2026-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2026-05-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2026-05-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2026-02-13 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-02-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-01-22 | Herabstufung | Truist | Buy → Hold |
| 2025-12-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-26 | Hochstufung | Truist | Hold → Buy |
| 2025-11-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-11-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-24 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-08-05 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-08-05 | Herabstufung | Truist | Buy → Hold |
| 2024-11-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-04-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-19 | Eingeleitet | Jefferies | Buy |
| 2024-01-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-12-13 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-11-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-11-03 | Hochstufung | Oppenheimer | Underperform → Perform |
| 2020-09-22 | Eingeleitet | JP Morgan | Overweight |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-07-15 | Eingeleitet | Goldman | Buy |
| 2020-06-18 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-18 | Eingeleitet | Lake Street | Buy |
| 2020-04-28 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-28 | Eingeleitet | Oppenheimer | Underperform |
| 2020-01-27 | Eingeleitet | Oppenheimer | Underperform |
| 2019-11-06 | Hochstufung | Berenberg | Sell → Hold |
| 2019-02-05 | Eingeleitet | Dougherty & Company | Buy |
| 2018-11-28 | Eingeleitet | Berenberg | Sell |
| 2018-10-29 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-29 | Eingeleitet | Guggenheim | Buy |
| 2018-05-29 | Eingeleitet | Stifel | Buy |
| 2018-05-29 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Inspire Medical Systems Inc Aktie (INSP) Neueste Nachrichten
Here's How Tempus AI Demonstrates Improving Operating Leverage - Zacks Investment Research
A director receives 203 shares instead of cash fees at Inspire Medical Systems (INSP). - Stock Titan
A director receives 284 shares instead of cash fees at Inspire Medical Systems (INSP) - Stock Titan
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo! Finance Canada
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo Finance
Truist Securities Adjusts Inspire Medical Systems PT to $78 From $62, Maintains Hold Rating - Yahoo Finance
Inspire Medical Systems Inc. (US4577301090.SG) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Mizuho Securities Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Inspire Medical Systems Inc (INSP) Shares Surge 3.8% -- What GF Score of 64 Tells Investors - GuruFocus
Free cash flow per share of Inspire Medical Systems, Inc. – HAM:2DR - TradingView
Price to cash flow ratio of Inspire Medical Systems, Inc. – HAN:2DR - TradingView
Inspire Medical Systems Inc. (US4577301090.SG) Q1 FY2026 earnings call transcript - Yahoo Finance
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo! Finance Canada
Inspire Medical Systems Inc (INSP) Stock Up 3.3% and Still Undervalued -- GF Score: 64/100 - GuruFocus
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Inspire Medical Systems, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Inspire Medical Systems Price Target Announced at $65.00/Share by Barclays - Moomoo
Barclays Initiates Inspire Medical Systems at Underweight With $65 Price Target - marketscreener.com
Barclays Initiates Inspire Medical Systems at Underweight With $65 Price Target - Yahoo Finance
Inspire Medical Systems Inc (INSP) Shares Fall 3.6% -- What GF S - GuruFocus
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 - Yahoo Finance UK
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 - Yahoo! Finance Canada
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 - Yahoo Finance
How Investors Are Reacting To Inspire Medical Systems (INSP) Securing Category I CPT Codes For Inspire V - Yahoo Finance
Medical Devices & SuppliesSpecialty Stocks Q2 Earnings Review: Inspire Medical Systems (NYSE:INSP) Shines - Yahoo Finance
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation - Zacks Investment Research
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation - TradingView
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation - Yahoo Finance
Inspire Medical (INSP): How Much Optimism Is Baked Into This Medtech Stock? - Yahoo Finance
RBC Capital Initiates Inspire Medical Systems(INSP.US) With Hold Rating, Announces Target Price $75 - Moomoo
Inspire Medical Systems, Inc. (INSP) stock price, news, quote and history - Yahoo Finance UK
INSP Maintains Buy Rating by Freedom Capital Markets -- Price Ta - gurufocus.com
Freedom Capital Markets maintains Buy rating on Inspire Medical Systems, $97 price target - TradingView
Top Inspire Medical Systems (INSP) Competitors 2026 - marketbeat.com
Inspire Medical receives new CPT codes for sleep apnea device - Investing.com
Inspire Medical Systems (INSP) Gains CPT Code Approval for Inspi - gurufocus.com
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel - The Manila Times
More than 140,000 patients have been treated for sleep apnea with Inspire. New billing codes are scheduled for 2028. - Stock Titan
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel - Yahoo Finance
Inspire Medical Systems Is Maintained at Sector Perform by RBC Capital - Moomoo
RBC Raises Price Target on Inspire Medical Systems to $75 From $60, Keeps Sector Perform Rating - marketscreener.com
INSP Maintained by RBC Capital -- Price Target Raised to $75 - gurufocus.com
Inspire Medical Systems Gets New CPT Codes for Hypoglossal Nerve Stimulation - Yahoo Finance
Inspire Medical Systems (NYSE:INSP) Stock Forecast & Analyst Predictions - Simply Wall Street
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo Finance
Inspire Medical Systems Inc (INSP) Stock Down 5.2% -- Now Underv - gurufocus.com
Inspire Medical Systems (INSP) Stock Could Be A Bargain On Cash Flow - Yahoo Finance
Inspire Medical Systems Inc (INSP) Stock Up 4.5% and Still Under - gurufocus.com
2DR Forecast — Price Target — Prediction for 2027 - TradingView
Finanzdaten der Inspire Medical Systems Inc-Aktie (INSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inspire Medical Systems Inc-Aktie (INSP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| JASON P KELLY | Officer |
Aug 07 '26 |
Proposed Sale |
59.55 |
963 |
57,342 |
0 |
| Kelly Jason P | See Remarks |
Aug 07 '26 |
Sale |
59.55 |
963 |
57,347 |
18,985 |
| Rondoni John | See Remarks |
May 15 '26 |
Sale |
43.28 |
2,641 |
114,302 |
27,165 |
| JOHN RONDONI | Officer |
May 15 '26 |
Proposed Sale |
43.28 |
2,641 |
114,304 |
0 |
| Rondoni John | See Remarks |
May 14 '26 |
Sale |
43.01 |
700 |
30,107 |
29,806 |
| JOHN RONDONI | Officer |
May 14 '26 |
Proposed Sale |
43.01 |
700 |
30,106 |
0 |
| mcCormick Shawn | Director |
May 08 '26 |
Sale |
45.31 |
696 |
31,536 |
27,712 |
| SHAWN T MCCORMICK | Director |
May 08 '26 |
Proposed Sale |
45.57 |
696 |
31,717 |
0 |
| JOHN RONDONI | Officer |
Jan 09 '26 |
Proposed Sale |
95.00 |
109 |
10,355 |
0 |
| Rondoni John | See Remarks |
Jan 09 '26 |
Sale |
100.00 |
109 |
10,900 |
13,797 |
5.27%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):